# US 2016/0257645 A1 · Inhibitors of human immunodeficiency virus replication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257645 A1
- Document ID: US20160257645A1
- Status: Published application
- Kind: A1
- Application number: 15/031,352
- Filed: 2014-10-23
- Published: 2016-09-08
- Earliest claimed: 2013-10-24
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Annapurna Pendri; Guo Li; John A. Bender; Zhong Yang; Alan Xiangdong Wang; Brett R. Beno; Robert A. Fridell; Makonen Belema; Nicholas A. Meanwell; Robert G. Gentles
- Web page: https://patentgrep.com/patent/US20160257645A1

## CPC

- C07C 311/58: having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
- A61P 31/18: for HIV
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/10: with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D 213/56: Amides
- C07D 215/08: with acylated ring nitrogen atom
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 265/36: condensed with one six-membered ring
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 277/82: Nitrogen atoms
- C07D 307/38: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 317/46: condensed with one six-membered ring
- C07D 317/66: Nitrogen atoms not forming part of a nitro radical
- C07D 333/18: by sulfur atoms
- C07D 333/28: Halogen atoms
- C07D 333/54: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 491/08: Bridged systems
- C07D 495/04: Ortho-condensed systems
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula: (I)

## Claims

### Claim 1

A compound of Formula I, including pharmaceutically acceptable salts thereof:
wherein:
R1 is alkyl, aryl, arylalkyl, cycloalkyl or heteroaryl; wherein said aryl, arylalkyl or heteroaryl moieties are linked to the parent molecule through their respective carbon atoms, and further wherein said R1 groups are substituted with 0-4 groups independently selected from the group of alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, alkyl, alkylsulphonyl, alkylthioxy, aminocarbonyl, alkynyl, carboxylic acid, cyano, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, thioxy, —SO2alkyl, heteroaryl, and nitro;
R2 is —H, C1-C4 alkyl or C3-C4 cycloalkyl;
or R1 and R2 together with the atoms to which they are attached form a heterocyclic ring optionally substituted with 0-2 alkyl groups;
R3 is —H, C1-C4 alkyl or C3-C4 cycloalkyl;
R4 is —H, alkyl, aryl, C5-C10 bicycloalkyl, cycloalkyl or heteroaryl which is substituted with 0-3 groups independently selected from the group of alkenoxy, alkenyl, alkoxy, alkoxycarbonyl, alkyl, benzyloxy, carboamide, cyano, halo, haloalkyl, haloalkoxy, —NHCO(alkyl), —SO2N-heterocycle, —OH, nitro, and —CH2OH;
R5 and R6 are independently selected from H or alkyl, or R5 and R4 together with the atom to which they are attached form an aryl group, or R5 and R6 together with the atoms to which they are attached form a C3-C4 cycloalkyl;
R7 is —H, alkyl, aryl, heteroaryl, heteroarylalkyl, C3-C7 cycloalkyl or dialkylaminoalkyl, wherein said aryl or heteroaryl is substituted with 0-3 groups independently selected from the group of —OH, —NHCOalkyl, —NHCON(alkyl)2, —NHCO2-alkyl, —CONH2, —CN, —SO2N(alkyl)2, alkoxy, alkyl, halo, haloalkoxy, and haloalkyl; and
R8 is —H, alkyl, arylalkyl, cycloalkyl, haloalkyl or heteroarylalkyl;
or R7 and R8 together with the nitrogen atom to which they are attached form a heterocycle which is substituted with 0-3 groups independently selected from the group of alkyl, alkoxy, halo, —OH, —CN, and —SO2N(alkyl)2.

### Claim 2 (depends on 1)

A compound of claim 1, wherein R1 is aryl.

### Claim 3 (depends on 2)

A compound of claim 2, wherein R1 is phenyl, biphenyl or naphthalenyl.

### Claim 4 (depends on 1)

A compound of claim 1, wherein R1 is heteroaryl.

### Claim 5 (depends on 4)

A compound of claim 4, wherein R1 is selected from the group of thiophene, pyrrazolophenyl, furanylphenyl, pyridinylphenyl, pyrimidinylphenyl, thiophenylphenyl, benzothiophene, oxadiazolephenyl, indole, and azaindole.

### Claim 6 (depends on 1)

A compound of claim 1, wherein R1 and R2 form a heteroaryl ring.

### Claim 7 (depends on 6)

A compound of claim 6, wherein said heteroaryl ring is isothiazolidine 1,1-dioxide.

### Claim 8 (depends on 1)

A compound of claim 1, wherein R4 is aryl.

### Claim 9 (depends on 8)

A compound of claim 8, wherein R4 is phenyl, naphthanenyl, or biaryl.

### Claim 10 (depends on 1)

A compound of claim 1, wherein R4 is heteroaryl.

### Claim 11 (depends on 10)

A compound of claim 10, wherein R4 is triazole or thiophene.

### Claim 12 (depends on 1)

A compound of claim 1, wherein R7 is aryl.

### Claim 13 (depends on 12)

A compound of claim 12, wherein R7 is phenyl or naphthalenyl.

### Claim 14 (depends on 1)

A compound of claim 1, wherein R7 is heteroaryl.

### Claim 15 (depends on 14)

A compound of claim 14, wherein R7 is selected from the group of bezodioxolyl, dihalobezodioxolyl, benzothiazole, quinoline, benzothiazole, benzimidazole, quinazoline, quinoxaline, dihydrobenzofuran, chroman, benzoxazole, isoquinoline, and isoquinolinone.

### Claim 16 (depends on 1)

A compound of claim 1, wherein R7 and R8 together form a heterocycle which is selected from the group of tetrahydroisoquinoline, dihydro-benzo[1,4]oxazine, dihydroindole, tetrahydrothieno[3,2-c]pyridine, 2-oxa-5-azabicyclo[2.2.1]heptanes, azetidine, and pyridinylpyrrolidine.

### Claim 17

A compound, including pharmaceutically acceptable salts thereof, which is selected from the group of:

### Claim 18

A compound, including pharmaceutically acceptable salts thereof, which is selected from the group of:

### Claim 19 (depends on 1)

A composition useful for treating HIV infection comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier, excipient and/or diluent.

### Claim 20 (depends on 1)

A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
